22 de marzo de 2019
17 de diciembre de 2010

COMUNICADO: Janssen solicita la autorización de comercialización europea de tealprevir para el tratamiento de la hepatitic C (y 2)

Referencias

---------------------------------

[1] The Hepatitis C Trust. The hepatitis C virus: Genotypes of HCV. [cited 2010 Nov 11] Available from: http://www.hepctrust.org.uk/hepatitis-c/The+hepatitis+C+virus

[2] World Health Organization. Hepatitis C, surveillance and control. [cited 2010 November 29] Available from: http://www.who.int/csr/disease/hepatitis/whocdscsrlyo2003/en/index4.html

[3] Biggins SW. Treatment of recurrent hepatitis C after liver transplantation. Infect Dis Clin North Am. 2006 Mar;20(1):155-74.

[4] Buskila D. Hepatitis C Associated Rheumatic Disorders. Rheum Dis Clin N Am. 2009;35:111-123.

[5] Lang K, Weiner DB. Expert Rev Vaccines. "Immunotherapy for HCV infection: next steps." 2008;7(7): 915-923.

[6] The Hepatitis C Trust. Introduction: Potential New Drugs. [cited 2010 Oct 19] Available from: http://www.hepctrust.org.uk/treatment/potential-new-drugs

[7] The Hepatitis C Trust. Treatment: Retreatment. [cited 2010 Oct 19] Available from: http://www.hepctrust.org.uk/treatment/Retreatment

[8] McHutchison, J, Jacobson, I, and Dusheiko, G et al. Telaprevir in Combination with Peginterferon and Ribavirin in Genotype 1 HCVTreatment-Naive Patients: Final Results of Phase 3 ADVANCE Study. Presented at AASLD 2010. Boston, USA.

[9] Sherman, K, Flamm, S, and Afdhal, N et al. Telaprevir in Combination with Peginterferon and Ribavirin in Genotype 1 HCVTreatment-Naive genotype 1 HCV Patients who achieved an Extended Rapid Viral Response: Final Results of Phase 3 ILLUMINATE Study. Presented at AASLD 2010, Boston, USA

[10] Janssen data on file

Contacto: Daniel De Schryver, Móvil: +49-173-7689-149

Emisor: Janssen-Cilag International

Contacto: Daniel De Schryver, Móvil: +49-173-7689-149

CONTACTO: Contacto: Daniel De Schryver, Móvil: +49-173-7689-149